TetraLogic Pharmaceuticals Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $11,674,480 against $8,787,101 a year ago. Net loss was $11,873,047 or $0.51 per diluted share against $9,354,438 or $0.42 per diluted share a year ago. Adjusted net loss was $10,153,521 or $0.44 per basic and diluted share against $7,103,809 or $0.32 per basic and diluted share a year ago.

For the six months, the company reported loss from operations of $22,304,522 against $14,418,135 a year ago. Net loss was $24,556,029 or $1.07 per diluted share against $14,688,505 or $0.67 per diluted share a year ago. Adjusted net loss was $18,938,983 or $0.82 per basic and diluted share against $11,909,218 or $0.32 per basic and diluted share a year ago.